The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy

References

• Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3–s13.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466.
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160–184.
   PubMed Web of Science ®Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403–E2412.
   PubMed Web of Science ®Google Scholar
• Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid. 2012;19(Suppl 1):65–67.
   PubMed Web of Science ®Google Scholar
• Zaros C, Genin E, Hellman U, et al. On the origin of the transthyretin Val30Met familial amyloid polyneuropathy. Ann Hum Genet. 2008;72(4):478–484.
   PubMed Web of Science ®Google Scholar
• Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy. J Med Genet. 2004;41(4):e51–e51.
   PubMed Web of Science ®Google Scholar
• Hund E. Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet. 2012;5:37–41.
   PubMedGoogle Scholar
• Lamb, YN, Deeks, ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79(8):863–874.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Obici L, Gorevic P, Lin H, et al. Indirect treatment comparison of the efficacy of patisiran and inotersen for hATTR amyloidosis with polyneuropathy. Paper presented at: 2019 Peripheral Nerve Society (PNS) Annual Meeting, 2019 June 22–26; Genoa, Italy.
   Google Scholar
• Planté-Bordeneuve V, Lin H, Gollob J, et al. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Exp Opin Pharmacother. 2018;20(4):473–481.
   PubMed Web of Science ®Google Scholar
• Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Stat Med. 2003;22(19):2995–3016.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429–437.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124.
   PubMed Web of Science ®Google Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21(16):2313–2324.
   PubMed Web of Science ®Google Scholar
• Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62(8):857–864.
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Morris D, et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861–1881.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11(1):159.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Welton NJ, et al. Evidence synthesis for decision making 3:heterogeneity – subgroups. Med Decis Making. 2013;33(5):618–640.
   PubMed Web of Science ®Google Scholar
• Cope S, Zhang J, Saletan S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12(1):93.
   PubMed Web of Science ®Google Scholar
• Gagnier JJ, Morgenstern H, Altman DG, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. BMC Med Res Methodol. 2013;13(1):106.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33(5):597–606.
   PubMed Web of Science ®Google Scholar
• Phillippo D, Ades T, Dias S, et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. Technical Support Documents, vol. 18, NICE Decision Support Unit, Decision Support Unit, ScHARR, University of Sheffield; 2016.
   Google Scholar
• Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak. 2013;13(1):72.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181.
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19(2):104–114.
   PubMed Web of Science ®Google Scholar
• Eastern Virginia Medical School. Manual and scoring algorithm for QOL-DN. Norfolk (VA): Eastern Virginia Medical School; 2006.
   Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497–508.
   PubMedGoogle Scholar
• Institute for Clinical and Economic Review. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value. Boston (MA): The Institute for Clinical and Economic Review (ICER); 2018.
   Google Scholar
• Salvo EM, Samjoo IA, Tran D, et al. Letter to the editor concerning the article: “An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy”. Expert Opin Pharmacother. 2019;20(12):1527–1528.
   PubMed Web of Science ®Google Scholar